Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device

Human Gene Therapy Methods

Volumn 26, Issue 4, 2015, Pages 134-146

  Amante, Dinah H ^a   Smith, Trevor R F ^a   Mendoza, Janess M ^a   Schultheis, Katherine ^a   McCoy, Jay R ^a   Khan, Amir S ^a   Sardesai, Niranjan Y ^a   Broderick, Kate E ^a  

^a Inovio Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; PLASMID DNA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG DELIVERY DEVICE; ELECTRODE; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSFECTION; GUINEA PIG; HEMAGGLUTINATION INHIBITION TEST; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; KERATINOCYTE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SKIN BIOPSY; SKIN SURFACE; SKINFOLD THICKNESS; STABLE EXPRESSION; ANIMAL; DERMIS; DEVICES; EPIDERMIS; GENE EXPRESSION; GENE TRANSFER; GENETICS; IMMUNOLOGY; METABOLISM; PLASMID; PROCEDURES; REPORTER GENE; RHESUS MONKEY; SKELETAL MUSCLE; SKIN;

CAVIA; PRIMATES;

ANIMALS; DERMIS; ELECTROPORATION; EPIDERMIS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; GUINEA PIGS; MACACA MULATTA; MUSCLE, SKELETAL; PLASMIDS; SKIN; VACCINES, DNA;

EID: 84939807562     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2015.020     Document Type: Article

References (38)

1. Tobin DJ. Biochemistry of human skin - our brain on the outside. Chem Soc Rev 2006;35:52-67.
2. Toebak MJ, Gibbs S, Bruynzeel DP, et al. Dendritic cells: biology of the skin. Contact Dermatitis 2009;60:2-20.
3. Nickoloff BJ, Turka LA, Mitra RS, et al. Direct and indirect control of T-cell activation by keratinocytes. J Invest Dermatol 1995;105:25S-29S.
4. Weiner DB. DNA vaccines: crossing a line in the sand [introduction to special issue]. Vaccine 2008;26:5073-5074.
5. Donnelly JJ, Ulmer JB, and Liu MA. DNA vaccines. Life Sci 1997;60:163-172.
6. Andre S, Seed B, Eberle J, et al. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998;72:1497-1503.
7. Sardesai NY, and Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011;23:421-429.
8. Martinon F, Kaldma K, Sikut R, et al. Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther 2009;20: 1291-1307.
9. Song JM, Kim YC, Lipatov AS, et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B-and T-cell responses in mice. Clin Vaccine Immunol 2010;17: 1381-1389.
10. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999;6:508-514.
11. Otten G, Schaefer M, Doe B, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004;22:2489-2493.
12. Otten GR, Schaefer M, Doe B, et al. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006;24:4503-4509.
13. Prud'homme GJ, Draghia-Akli R, and Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther 2007;14:553-564.
14. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164: 4635-4640.
15. Mir LM, and Orlowski S. The basis of electrochemotherapy. Methods Mol Med 2000;37:99-117.
16. Orlowski S, Belehradek J, Jr., Paoletti C, et al. Transient electropermeabilization of cells in culture: increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988;37:4727-4733.
17. Kopycinski J, Cheeseman H, Ashraf A, et al. A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the a4b7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol 2012;19: 1557-1559.
18. Diaz CM, Chiappori A, Aurisicchio L, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med 2013;11:62.
19. Chudley L, McCann K, Mander A, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012;61:2161-2170.
20. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6:e19252.
21. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4:155ra138.
22. Broderick KE, Shen X, Soderholm J, et al. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther 2011;18:258-265.
23. Roos AK, Eriksson F, Timmons JA, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009;4:e7226.
24. Roos AK, Moreno S, Leder C, et al. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006;13:320-327.
25. El-Kamary SS, Billington M, Deitz S, et al. Safety and tolerability of the Easy Vax clinical epidermal electroporation system in healthy adults. Mol Ther 2012;20:214-220.
26. Hirao LA, Wu L, Khan AS, et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008;26:440-448.
27. Laddy DJ, Yan J, Khan AS, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009;83:4624-4630.
28. Hirao LA, Draghia-Akli R, Prigge JT, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2010;203:95-102.
29. Diehl MC, Lee JC, Daniels SE, et al. Tolerability of intramuscular and intradermal delivery by CELLECTRA - adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother 2013;9:2246.
30. Mendoza JM, Amante, DH, Kichaev G, et al. Elucidating the kinetics of expression and immune cell infiltration resulting from plasmid gene delivery enhanced by surface dermal electroporation. Vaccines 2013;1:384-397.
31. Smith TRF, Schultheis K, Kiosses WB, et al. DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther Methods Clin Dev 2014;1:14054.
32. Yan J, Corbitt N, Pankhong P, et al. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine 2011;29:7173-7181.
33. Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013;208: 818-829.
34. Lin F, Shen X, Kichaev G, et al. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods 2012;23: 157-168.
35. Heller LCJ, Coppola MJ, McCray D, et al. Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther 2007;14:275-280.
36. Roos AK, Eriksson F, Walters DC, et al. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther 2009;17:1637-1642.
37. Gronevik E, Von Steyern FV, Kalhovde JM, et al. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med 2005;7:218-227.
38. Hutnick NA, Myles DJ, Bian CB, et al. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 2011;1: 233-240.